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AbstrACt
Testicular cancer (TC) is by far the most common cancer 
to affect young men; however, the exposures that cause 
this disease are still poorly understood. Our own research 
has shown that Māori men have the highest rates of this 
disease in New Zealand—a puzzling observation, since 
internationally TC is most commonly a disease of men of 
European ancestry. These trends provide us with a unique 
opportunity: to learn more about the currently unknown 
exposures that cause TC, and to explain why Māori have 
the highest rates of this disease in New Zealand. Using 
epidemiology and genetics, our experienced research team 
will conduct a nationwide study which aims to answer 
these internationally important questions.
Aim of study The overall aim of the current national 
case–control study is to identify the key exposures in the 
development of TC in New Zealand, and explore which 
factors might explain the difference in the incidence of TC 
between Māori and non-Māori.
Methods and analysis Outside of our own investigations 
into cryptorchidism, we still do not know which exposures 
are driving the significant incidence disparity between 
ethnic groups in NZ. The aim of the proposed research is to 
use a population-based case–control study to identify the 
key exposures in the development of TC in New Zealand. 
We will recruit 410 TC cases and 410 controls, and collect 
(1) environmental exposure data, via interview and (2) 
genetic information, via genome-wide genotyping.
Ethics and dissemination Ethical approval for this study 
was sought and received from the New Zealand Ministry of 
Health’s Health and Disability Ethics Committee (reference 
# 17/NTA/248). Following a careful data interpretation 
process, we will disseminate the findings of this study to a 
wide and varied audience ranging from general academia, 
community groups and clinical settings, as well as to the 
participants themselves.
IntroduCtIon 
Testicular cancer (TC) is the most common 
cancer to affect young men, with disease 
incidence peaking between 15 and 40 years 
of age.1 Incidence rates of TC have been 
increasing rapidly over time, both interna-
tionally2 and in New Zealand.3 Despite a large 
body of research focused on this cancer, TC 
remains poorly understood—both in terms of 
what causes the disease, and also why certain 
populations are more likely to develop it than 
others.
Regarding higher risk for particular 
groups, there are several examples of 
puzzling epidemiological patterns for TC; for 
example, despite geographical proximity and 
very similar population demography, rates 
of disease among Norwegian men are two 
and a half times higher than those observed 
in Finland.4 In New Zealand, a dispropor-
tionately large number of TC cases occur 
in Māori men, with relative incidence rates 
80% higher in this ethnic group compared 
with European/other men (adjusted rela-
tive risk 1.80, 95% CI 1.58 to 2.05).5 This is in 
stark contrast to other countries, where white 
strengths and limitations of this study
 ► This study is the first to investigate the aetiology 
of testicular cancer in New Zealand, a country with 
highly unusual ethnic trends in the incidence of this 
disease.
 ► This is a national study, using robust cancer registry 
data to identify cases of testicular  cancer. it will use 
a case–control design, which is the most efficient 
means of addressing our research questions.
 ► One limitation of the study is that, due to the nature 
of the perinatal and early-childhood exposures we 
are examining, there is some risk of social stigma-
tisation and psychological distress of participants 
(particularly the mothers of cases/controls).
 ► Linked to this, there is also some risk of non-report-
ing of exposures that are considered socially unde-
sirable, as well as some risk of differential recall/
reporting between cases and controls.
 ► There are general limitations inherent to most 
case–control studies, including the potential for low 
recruitment rates (particularly of controls), and ret-
rospective reporting of exposures which could be 
differentially reported by cases and controls (recall 
bias). 
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men—particularly those who can trace their ancestry 
back to Northern Europe6—have by far the highest rates 
of disease compared with other ethnic groups.7 8 An addi-
tional factor is that Pacific New Zealanders have very low 
rates of TC compared with Māori and non-Māori/Pacific/
Asian men—a rare (if not singular) example where Māori 
and Pacific peoples do not move in parallel with respect 
to the incidence of a given disease.3 5 All of these unusual 
epidemiological trends remain unexplained.6–8
Aside from young age, the risk factors which have been 
shown to be most strongly associated with TC incidence 
include prior cancer of the opposite testicle,9 family 
history of TC10 and history of undescended testis also 
known as cryptorchidism.10 Given the rarity of these risk 
factors, they can only possibly explain a small proportion 
of cases.11
risk factors for tC
Other than age, cryptorchidism is the risk factor most 
strongly associated with TC development.1 It is known 
that men with a history of cryptorchidism have a three 
to sixfold increase in the risk of TC compared with those 
with no history of cryptorchidism.12 13 Our previous 
research has shown that ethnic trends in the incidence of 
cryptorchidism mirror those found for TC (see figure 1), 
whereby Māori boys are significantly more likely to have 
this condition than non-Māori/Pacific/Asian boys (rate 
ratio 1.24, 95% CI 1.15 to 1.34).14 Our observations of 
a parallel between TC and cryptorchidism incidence in 
New Zealand strongly suggest that ethnic differences in 
rates of cryptorchidism are associated with differing rates 
of TC—directly via a causal pathway and/or indirectly 
via common risk factors. Since the factors involved in the 
aetiology of cryptorchidism occur prenatally,15 it follows 
that at least some of the exposures driving these observed 
disparities occur prenatally.
Since the aetiology of TC remains obscure, a number of 
other potential risk factors have been investigated which 
could be important in the development of TC. These risk 
factors can be broadly grouped as either environmental 
or genetic, with environmental risk factors subclassi-
fied as prenatal and postnatal. Of these risk factors, the 
current study is most concerned with those which could 
plausibly explain the disparity observed between Māori 
and non-Māori New Zealanders with respect to the inci-
dence of TC and/or cryptorchidism.
Aims and research questions
The overall aim of the current study is to identify the key 
exposures in the development of TC in New Zealand, with 
a focus on those factors which might explain the incidence 
disparity between Māori and non-Māori men. By iden-
tifying these points of difference, we will likely increase 
international understanding of the key exposures which 
lead to the development of TC,3 14 making New Zealand 
a prime location for this important aetiological research.
The current study will aim to address the following 
questions:
1. How common are potential environmental risk factors 
for the development of TC in New Zealand, and how 
strongly are they associated with TC development in 
this context?
2. How does the prevalence of these environmental risk 
factors for TC differ by ethnicity, and to what extent 
might these risk factors explain the disparity in TC in-
cidence between Māori and non-Māori men?
3. How common are the known genetic risk factors for 
TC (eg, specific KITLG alleles) among New Zealand 
men, and how strongly are they associated with TC de-
velopment in this context?
4. How does the prevalence of these known genetic risk 
factors differ by ethnicity, and to what extent might 
these risk factors explain the disparity in TC incidence 
between Māori and non-Māori men?
5. Is there evidence for additional (as-yet undiscovered) 
predisposing genetic variants in Māori men, particu-




In order to answer our research questions, we will conduct 
a population-based case–control study in New Zealand. 
We will collect data on exposures occurring prenatally 
and in the prediagnostic period for cases and an equiv-
alent period for controls using self-report from cases/
controls and their mothers. We will also collect genetic 
data.
Questionnaire development
In order to develop the study questionnaires, we 
conducted a literature review of the key biologically plau-
sible exposures in the development of TC. Searches of 
electronic databases were conducted using Scopus, using 
relevant keywords and Boolean search terms. We also 
requested and received copies of study questionnaires 
from the corresponding authors of several other relevant 
published studies.
When developing the questionnaires, we focused on 
purported risk factors for TC where there was either 
Figure 1 Comparison of relative risk (95% CI) of 
cryptorchidism 1 and testicular cancer (TC) 3 in the New 
Zealand context, by ethnicity (data from Gurney et al514).
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clear or mixed evidence of an association with TC in 
the literature, as well as evidence of significant differen-
tial exposure between Māori and non-Māori. Both study 
questionnaires were developed over several years, based 
on previous questionnaires from other TC case–control 
studies,16–18 other questionnaires including the New 
Zealand Health Survey,19 and input from experts and key 
stakeholders.
The case/control questionnaire includes questions 
on: (1) history of cryptorchidism, inguinal hernia or 
hypospadias, including whether these conditions were 
corrected and at what age; (2) active and passive exposure 
to cannabis; (3) active and passive exposure to tobacco 
smoke, including known family history of tobacco use 
and type of cigarette (roll-your-own or factory manufac-
tured); (4) age at puberty and early sexual experiences 
(as proxies for puberty/sexual maturity); (5) occupa-
tional history, including pesticide exposure (among other 
exposures); (6) fertility, (7) achieved adult height and (8) 
known family history of TC and/or cryptorchidism. We 
have also included questions on alcohol intake, primarily 
with a view to controlling for this exposure as a poten-
tial confounder of the relationship between tobacco and 
cannabis exposure and TC development.
The questionnaire for the birth mother of the case/
control will include questions on: (1) maternal (and 
paternal) smoking, including type of cigarette; (2) gesta-
tional age at delivery; (3) birth weight; (4) maternal use 
of cannabis and other drugs and (5) recollection of any 
other unusual prenatal events, including nausea beyond 
the first trimester, excessive maternal weight gain and 
bleeding. In addition, mothers will be asked for their 
recollection of (1) cryptorchidism, inguinal hernia or 
hypospadias occurrence in their son, including whether 
this condition was corrected and at what age; (2) age of 
son’s puberty and (3) family history of TC and/or crypt-
orchidism. We have also included questions on alcohol 
intake during pregnancy, for the reasons given above.
Participants
Case identification
Patients diagnosed with TC (‘cases’) will be identified 
via unique identifier (National Health Index (NHI) 
number) using the New Zealand Cancer Registry 
(NZCR). The NZCR is a national collection of all incident 
cases of malignancies in New Zealand, with the exclusion 
of squamous and basal cell malignancies.20 Only cases 
aged between 16 and 49 will be included in this study. 
The NHI number is attributed to all New Zealanders 
who use healthcare services (approximately 98% of the 
population), and the NHI database includes additional 
information including name, address, date of birth, place 
of birth, gender, residency status, ethnicity and date of 
death (if relevant).21 Indigenous Māori and non-Māori 
TC incident cases diagnosed over the 2010–2016 period 
will be the base for participant recruitment (approxi-
mately 1050 cases or 150 cases/year22). Once identified 
via the NZCR, TC cases will be linked to the NHI database 
via their unique NHI identifier. If the participant has no 
recorded date of death on the NHI, the process of case 
recruitment will begin (figure 2). Given the high surviv-
ability of TC in New Zealand (5-year survival: European/
other 98%, Māori 92%),5 coupled with the young median 
age at diagnosis (European/other 38 years, Māori 31 
years),5 the proportion of men who would have died since 
their diagnosis is expected to be less than 5%.
Control identification
For every recruited case, one age-matched and ethnici-
ty-matched control will be recruited from the general 
population. Controls will be identified from the NHI data-
base, and frequency matched to cases on the basis of age 
(5-year age groups) and ethnicity (Māori/non-Māori).
Case/control recruitment
Once cases and controls have been linked to the NHI, a 
letter of invitation and information about the study will 
be sent to each potential case and control, inviting indi-
viduals to contact the study coordinator to discuss the 
study and obtain consent.
Figure 2 Strategy for identifying and recruiting cases and 
controls. NHI, National Health Index; NZCR, New Zealand 
Cancer Registry; PIS/CF, Participant Information Sheet/
Consent Form. 
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Interview of cases/controls
Interviews with eligible participants will be available face-
to-face interview, by telephone or online. If the partici-
pant decides to complete the survey over the telephone or 
online, a separate face-to-face appointment will be made 
with them in order to collect the saliva sample required 
for the genetic component of the study.
recruitment of mothers of cases/controls
At the time of the interview with cases/controls, the 
participants will be asked for their consent for the study 
team to contact their mothers. If the mother is inter-
ested in participating, the study coordinator will make 
arrangements regarding an interview either by telephone 
or online. Cases/controls will not be excluded if their 
mother is unable or unwilling to participate (see table 1 
regarding approaches to managing potential bias from 
missing maternal data).
data collection
Two forms of information will be collected for this case–
control study: (1) interview information and (2) genetic 
information. This section further details the information 
to be gathered during data collection.
Interview data will be used to determine those prenatal 
and postnatal environmental exposures which are more 
common among those with TC than those without, as 
well as ethnic differences in exposure prevalence. Two 
questionnaires have been developed to identify the preva-
lence of exposure among cases and controls to a number 
of TC risk factors. One questionnaire will be answered 
by the case/control (Case/Control Questionnaire), and 
a second questionnaire will be answered by the mother 
of the case/control (Mother of Case/Control Question-
naire). The study questionnaires, including the source 
of individual questions, where relevant, are available on 
request from the lead author.
Genetic data will be used to determine the preva-
lence of risk alleles among New Zealand men, and how 
the prevalence of risk alleles differs between cases and 
controls, stratified by ethnicity. DNA samples will be taken 
from cases/controls via saliva sample, using the Oragene 
OG-500 kit (DNA Genotek, Ottawa, Canada). Collection 
of DNA via saliva at the time of the interview removes the 
need for participants to visit a blood collection centre, 
and also removes the need for the use of invasive needles. 
The sample will be taken by interviewers and packaged 
in laboratory bags, which will have a sticker attached to 
them that includes only the unique study identifier for 
the participant (ie, no identifiable information). The 
laboratory bag will then be delivered to a genetics labo-
ratory for preparation of genomic DNA and subsequent 
analysis. At this laboratory, genome-wide genotyping will 
be performed with only those ~40 loci already known 
to be associated with TC by genome-wide association 
studies specifically interrogated.23–26 The genotyping will 
be performed on an appropriate GWAS platform such 
as the Illumina CoreExome array. The primary reason 
for using a genome-wide platform to collect the data on 
the ~40 known TC loci is as follows: (1) genome-wide 
genotyping is a practical cost-effective way to genotype 
multiple single nucleotide polymorphisms over multiple 
candidate loci (research questions 3 and 4) and (2) 
genome-wide genotyping data could, in future, allow a 
full genome-wide association study which would allow 
us to examine our data for evidence of additional vari-
ants in Māori that might explain our observed disparity 
(eg, a rare, highly penetrant variant; research question 
5). Access to genomic data for this future genome-wide 
association study would be governed by our Kaitiaki-
tanga (Guardianship) Group (see the Data management 
section). Following genotyping, the resulting raw data will 
be processed by an experienced bioinformatician, and 
analysis will be carried out in conjunction with the wider 
team.
Transport, storage and analyses of genetic specimens
We have dedicated substantial time and resources into 
developing robust protocols around collection and 
transport of samples, built on the advice and steering of 
senior Māori health researchers and key stakeholders. 
We have decided that samples (and/or the resulting 
genomic data) will not be sent overseas to large analysis 
facilities (which would be highly cost-effective)—rather, 
all handling of specimens and analyses will be conducted 
in New Zealand. A unique study identifier (and no other 
identifying information) will be used to identify samples 
during transport and analysis. Importantly, specimens 
collected for this study will not be used for any purpose 
other than those declared to participants during the study 
consent process.
To mitigate the potential risk of losing valuable infor-
mation by destroying all biospecimens, we will ask 
participants for permission to retain the genome-wide 
genotyping data collected for the study beyond the end of 
the study, access to which will be governed by our Kaitiaki-
tanga (Guardianship) Group. As mentioned above, 
retaining this genome-wide genotyping data could, in 
future, allow a full genome-wide association study which 
would allow us to examine our data for evidence of addi-




In addition to descriptive analyses, multivariable logistic 
regression methods (non-conditional, due to frequency 
matching approach) will be used to determine the 
odds of TC among those exposed to a given exposure 
compared with those who were not exposed, adjusted 
for confounding factors. This regression analysis will 
be completed both for the whole study population (ie, 
all cases/controls), and also stratified by ethnic group 
(Māori and non-Māori). From these analyses, ORs and 
their confidence limits will be calculated.
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Table 1 Study risks and approach to their management
Potential risk Approach to risk management
1. Insufficient total cases/controls.  ► Maximise response rate by creating multiple possible modes of participation.
 ► Potentially extend period of case definition (beyond 2010–2016) if necessary.
2. Insufficient Māori cases/controls, that is, to 
allow stratified analysis.
 ► Maximise response rate by creating multiple possible modes of participation.
 ► Potentially extend period of case definition (beyond 2010–2016) if necessary.
 ► Increase oversampling of Māori (and thus no of Māori recruited into the study).
 ► Potentially extend period of data collection.
3. Selection bias of cases, that is, testicular 
cancer (TC) cases included in study are not 
representative of TC cases generally in terms of 
exposures.
 ► Should be small as TC is uncommon and all diagnosed cases appear on the New 
Zealand Cancer Registry (NZCR).
 ► Characteristics of consenting cases (age, ethnicity, deprivation) can be compared with 
all NZCR TC cases to see if there are any systematic differences.
 ► If clear differences are observed, we will consider and document how this difference 
may impact the exposure information collected from cases.
4. Selection bias of controls, that is, controls 
included in study are not representative of source 
population in terms of important exposures 
(eg, those who agree to participate may 
systematically differ in some way to those who 
do not).
 ► Characteristics of consenting controls (age, ethnicity, deprivation) can be compared with 
the general population to see if there are any systematic differences.
 ► If clear differences are observed, we will consider and document how this difference 
may impact the exposure information collected from controls.
5. Information bias—case/control 
misclassification, for example, cases incorrectly 
diagnosed as TC, controls incorrectly diagnosed 
as non-cases.
 ► Because cancers registered on the NZCR are histologically confirmed, and because we 
will ask cases and controls whether they had a previous TC diagnosed prior (or since) 
the study period (2010–2016), risk of case or control misclassification is very minimal.
6. Information bias—poor recall of some 
exposures by cases and controls (non-differential) 
especially early childhood exposures.
 ► Ask cases/controls questions that they are likely to recall, and minimise questions that 
refer to early to mid-childhood
 ► Ask mothers of cases/controls questions that they are likely to recall (eg, smoking during 
pregnancy or exposure to cannabis), and minimise questions that are difficult to recall 
(eg, heaviness of bleeding during menstrual cycle prior to index pregnancy).
7. Information bias—differential recall of those 
exposures that are asked of both mothers and 
sons.
 ► Give way rule: if exposures pertain to pregnancy and childhood, exposure information 
from mothers will be preferred to that from sons when interpreting data (although both 
will be presented).
 ► Give way rule: if exposures pertain to adolescence, exposure information from 
adolescence onwards, exposure information from sons will be preferred to that from 
mothers.
8. Information bias—non reporting of exposures 
that are considered socially undesirable (eg, 
cannabis use by cases/controls, smoking during 
pregnancy by mothers).
 ► Prior to answering questions about cannabis use/exposure, cases and controls will be 
informed that their answers will be completely confidential within the study team.
 ► Cases/controls: In the first instance, encourage cases/controls to complete the interview 
face to face. When asking questions for which the answer may be socially undesirable, 
the interviewer can pass digital tablet to the case/control, so that they can answer the 
question(s) without the interviewer knowing their answer.
 ► Mothers: In the first instance, encourage mothers to complete the study questionnaire 
online (ie, without an interviewer asking the questions).
9. Information bias—language difficulties and 
cultural differences creating non-differential recall 
of exposures by cases and controls.
 ► Using an experienced interviewing service with a track record of cultural competency.
 ► Where possible, match interviewers to participants on ethnicity (Māori/non-Māori).
10. Information bias—differential recall of 
exposures by cases and controls.
 ► Use identical questions for cases and controls.
 ► Do not provide information on specific hypotheses being tested.
 ► Do not ask questions about exposures immediately prior to illness (for cases), since this 
is a different period to controls.
11. Information bias—differential effort by 
interviewer to identify exposures for cases and 
controls and their mothers (interviewers will not 
be blinded to case/control status).
 ► Ensure that interviewers stick to the carefully constructed questionnaire (including 
preambles before questions) when conducting face-to-face and telephone interviews.
 ► Have an online option for completing the study questionnaire, which cannot be 
influenced by this potential bias.
12. Risks associated with retaining genome-wide 
genotyping data.
 ► No biospecimens will be banked for the purposes of unspecified future research.
 ► Genomic data for the current study will only ever be used to investigate the aetiology of 
TC, with the express consent of participants for using the data in this manner.
 ► Genomic data will never leave New Zealand, but will only be analysed by the study 
team.
 ► Control of the use of the genomic data collected for this study will rest with the 
Kaitiakitanga (Guardianship) Group, comprised senior Māori members of the study team, 
a cancer consumer representative and a representative from our Mother’s Advisory 
Group.
Continued
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Genetic data
Logistic regression methods will be used to determine the 
odds of TC among those exposed to a given risk allele 
compared with non-exposed—both for the total cohort 
(ie, all cases/controls) and also stratified by ethnic group 
(Māori and non-Māori). From these analyses, ORs and 
their confidence limits will be calculated. In addition, we 
will describe the prevalence of given genetic risk alleles 
stratified by ethnic group. Both the individual associ-
ations between exposure to risk alleles and TC, as well 
as a quantification of the overall risk allele ‘burden’ (ie, 
the number of risk alleles presents in a given group), will 
also be determined.27 28 For future analysis, we will use 
the same statistical approaches (with relevant adjustment 
for multiple comparisons) to test for the presence of 
additional susceptibility variants among Māori across the 
whole genome, with particular focus on previously identi-
fied loci (ie, genome-wide association study).
Gene/environment interaction will be assessed by 
combining interview data with genetic data. Given our 
sample size, this work will be exploratory in nature. First, 
we will stratify on the genetic exposure and assess the inde-
pendent effect of the environmental exposure among 
those with and without the genetic exposure using logistic 
regression models. In addition, logistic regression models 
with an interaction term between relevant genetic and 
environmental exposures added to the baseline model 
will be fitted (ie, a model which includes the relevant 
genetic and environmental exposure independently). 
We will use decision rules to identify the gene–environ-
ment interactions that will be explored, whereby we will 
only include genetic and environmental factors that 
are shown to be associated with TC development in the 
adjusted models. The presence of a gene/environment 
interaction will be assessed using likelihood ratio tests 
between the baseline model(s) and the model(s) which 
include the interaction term.29 The detection of signifi-
cant gene–environment interactions will only be possible 
where strong interactions are present, since very large 
sample sizes are required to detect weaker interactions 
with reasonable statistical precision.29 As such, the basic 
stratified analysis—showing the distribution of the given 
environmental and given genetic exposure across cases 
and controls, with associated ORs—will form the primary 
results for this component of the study.
In summary, we will complete data analysis for the 
total combined sample of cases and controls, and also 
complete the same analysis stratified by ethnicity. For 
the combined analysis, we will (1) describe the preva-
lence of environmental and genetic exposures among TC 
cases and controls and (2) determine which exposures 
are important drivers of TC development in general. For 
the ethnicity-stratified analysis, we will (1) describe the 
prevalence of exposures among TC cases and controls, 
and whether this differs for Māori and non-Māori and (2) 
determine which exposures are important drivers of TC 
Potential risk Approach to risk management
13. Risks of stigmatising participants due to 
sensitive nature of some questions, for example, 
mother’s use of cannabis use during pregnancy.
 ► Data collection to be completed by CBG Health Research, a highly professional 
interviewing service who perform the NZ Health Survey for the Ministry of Health.
 ► Online option for participants, to ensure privacy when answering questions and remove 
the need for a participant to say their answer aloud.
 ► During face-to-face interviews, participants will be given a tablet to answer sensitive 
questions, to remove the need to say their answer aloud
 ► All data analysis to be completed by a small, culturally competent research group (JKG, 
DS, JS).
 ► Data interpretation to be assisted by wider study investigator group, who have 
substantial experience in competent data interpretation.
 ► Finally, data interpretation will be completed by three separate groups: (1) senior Māori 
members of the study team; (2) a small cancer consumer group and (3) a Mother’s 
Advisory Group.
14. Risks of psychological distress due to 
sensitive nature of some questions, for example, 
mother’s sense of self-blame when answering 
questions about exposures during pregnancy.
 ► Data collection to be completed by CBG Health Research, a highly professional 
interviewing service who perform the NZ Health Survey for the Ministry of Health.
 ► Participants will be reminded throughout the process (preinterview, during interview, 
after interview) that just because we are asking questions about an exposure does not 
mean that the exposure causes TC.
 ► In the lay summary of study results, participants (specifically cases and their mothers) 
will be reassured that just because we may have found an association between a given 
exposure and the development of TC at a study level, that does not mean that their 
cancer was caused by that exposure.
 ► Interview to be immediately ceased by the interviewer as soon as a participant 
becomes psychologically distressed. If interviewing in person or over the telephone, the 
interviewer will remain talking to the participant and reassuring them until they are calm 
and happy, at which point the interview will end.
 ► The interviewer will also follow up the next day to ensure that the participant is feeling 
okay.
 ► The participant would not be asked to take part in the study again (unless they 
expressed a strong personal desire to do so).
Table 1 Continued 
7Gurney JK, et al. BMJ Open 2018;8:e025212. doi:10.1136/bmjopen-2018-025212
Open access
development for Māori, and whether these differ to those 
that are important for non-Māori.
sample size and statistical power
Total analysis
In order for the case–control study to have sufficient 
statistical power to detect an OR of 1.6 (80% power with 
95% CI) for reasonably common exposures (20%–70% 
underlying prevalence in control group), and greater 
ORs (95% CI 2.0 to 3.0) for rare (<20%) or very common 
(>70%) exposures, we require a sample size of 410 cases 
and 410 controls (Open Epi, V.3.0). As a realistic example 
of the likely statistical power of the study in terms of the 
genetic analysis, the risk allele frequency of the KITLG 
variant rs1508595 has been shown in TC genetics litera-
ture to be 83% among controls and 92% among TC cases, 
with an associated per-allele OR of 2.55 (95% CI 2.05 to 
3.18).27 The current study would be sufficiently powered 
to detect a difference in a prevalence of this magnitude 
(97% power, Open Epi, V.3.0). Adjustment for multiple 
comparisons (particularly when looking for evidence of 
relevant genetic variation across the whole genome) will 
reduce the power of the study from this nominal level.
Ethnicity-stratified analysis
Considering the focus of the study is to explain a disparity 
between Māori and non-Māori men, we aim to over-
sample the Māori population and recruit at least 150 
Māori TC cases and 150 controls. In addition to the wider 
case–control study, oversampling Māori will allow us to 
stratify by ethnicity, and conduct separate nested case–
control studies within ethnic groups (Māori stratified 
analysis: 150 cases vs 150 controls; non-Māori: 260 cases 
vs 260 controls). For Māori, a sample of 150 cases and 
150 controls has 80% power to detect an OR of 2.0 for 
relatively common exposures (25%–60% prevalence in 
control group) and 2.0–3.0 for less (or more) common 
exposures. For non-Māori, a sample of 260 cases and 260 
controls has 80% power to detect an OR of 1.7–1.8 for 
relatively common exposures (25%–70% prevalence in 
control group) and 2.0–3.0 for less (or more) common 
exposures. As an example of study power following strat-
ification by ethnicity, we would have sufficient power 
(80%) to detect a difference if 40% of the mothers of 
Māori cases smoked during pregnancy compared with 
25% of the mothers of Māori controls (OR 2.0).
data management
A Kaitiakitanga (Guardianship) Group—comprised 
the senior Māori members of the study team, as well as 
a cancer consumer representative and a representative 
from our Mother’s Advisory Group—will be created to 
provide guardianship over the data collected for this 
study. All interview and genomic data will be stored on 
password-protected computers. Once the final dataset 
is received by the study investigators, all identifiable 
information (including NHI number) will be deleted 
from the final master dataset. All data will be stored on a 
password-protected computer, and only ever accessed by 
a small group of the study investigators. Anytime that data 
are transferred electronically, this data will be encrypted 
with a password. The data will be stored for a minimum 
of 10 years.
Future use of genomic data
Regarding the potential future use of genome-wide geno-
typing data for the purposes of conducting a genome-wide 
association study (to identify additional as-yet undiscov-
ered predisposing genetic variants in Māori men, that 
is, research question 5 of the wider study), this would be 
tightly controlled by the study’s Kaitiakitanga (Guardian-
ship) Group. Our Kaitiakitanga (Guardianship) Group 
will need to unanimously approve any future use of 
genomic data prior to the study investigators seeking new 
ethical approval (or an amendment) to conduct further 
analysis. This will also be consented by the participants, 
and would be the subject of a new ethics application (or 
amendment to the existing study). This data would only 
ever be used to investigate the aetiology of TC.
study timelines
The study protocol and questionnaire have been devel-
oped over the course of the past several years. Data collec-
tion for the pilot phase of the study began in May 2018, 
with associated (minor) revisions to the study protocol 
made following this pilot study phase. The purpose of 
this pilot phase is to answer questions regarding logis-
tical operation of the study, including the following: (1) 
What are the difficulties associated with recruiting men 
into a TC case–control study? (2) How acceptable are the 
study questions to the cases/controls? (3) What are the 
difficulties associated with finding and interviewing their 
mothers, and what is the likely response rate for maternal 
questionnaires? and (4) What difficulties may be associ-
ated with the collection of oral swab or saliva samples, 
and what is the likely response rate for this component? 
Answering these questions will enable us to make minor 
adjustments to our study protocol (largely to maximise 
response rate).
We are currently seeking funding for the full study, and 
if successful within the 2018–2019 funding rounds we 
aim to have data collection, analysis and dissemination 
completed by the end of 2021.
Patient and public involvement
We are pleased to have the support of a small group of 
cancer consumers, who will consider the results from a 
cancer consumer’s perspective prior to dissemination 
of study findings. Participants will be invited to receive 
a lay summary of the study results, along with an expla-
nation of what these results might mean in the wider 
context of TC. This lay summary will begin by explaining 
in lay terms (aimed specifically at cases and their mothers) 
that the study-level findings do not necessarily mean that 
an individual’s cancer was caused by the exposures that 
were found to be most strongly associated with TC. These 
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summaries will be prepared by the wider study investi-
gator team, and screened by the senior Māori members 
of the team, the Mother’s Advisory Group and our group 
of cancer consumers to ensure that they minimise the risk 
of participant stigmatisation.
EthICs And dIssEMInAtIon
The study also underwent consultation with the Ngāi Tahu 
Research Consultation Committee (University of Otago), 
which is a committee that provides feedback on the study 
from an independent Indigenous Māori perspective.
data interpretation
All data analysis will be conducted by a small research 
team (JKG, DS, JS) comprised Māori and non-Māori 
researchers with a substantial history of conducting 
high-quality, culturally competent research (particularly 
in the area of health inequalities for Māori). Following 
data analysis, interpretation of the results will pass 
through multiple filters to ensure that the messages that 
are presented from the study are culturally competent 
and minimise the risk of stigmatising certain popula-
tion groups (eg, Māori). First, the initial interpretation 
of the study results will be conducted by the wider study 
investigator team. Second, smaller groups will consider 
then consider the interpretation made by the wider study 
group from unique perspectives: (1) the senior Māori 
members of the study team will consider the impact of 
the findings on Māori, and how best to disseminate the 
study findings; a small group of cancer consumers will 
consider the results from a cancer consumer’s perspec-
tive; and members of a Mother’s Advisory Group (created 
specifically for this study) will be asked to assess the study 
investigator’s interpretation of the study results, to ensure 
that these are presented in a manner that minimises the 
risk of stigmatisation of mothers (in general and specifi-
cally those involved in the study).
dissemination
The research team conducting this study is well placed 
to disseminate research findings to a wide and varied 
audience, ranging from general academia, community 
groups and clinical settings. Following the data interpre-
tation process outlined above, the principal investigator 
will ensure that research findings are summarised in a 
clear, concise and culturally appropriate manner to all 
participants and their whānau, and that these summa-
ries will also be more widely disseminated to the commu-
nity. We will also develop press releases and make these 
available to media. The principal investigators and wider 
research team will participate in meetings and workshops 
which are relevant to the current study, and disseminate 
our findings where appropriate. At the conclusion of 
the study, results will be made available as both printed 
and online resources, as well as in academic and clinical 
peer-reviewed journals and at conferences.
study risks and sources of bias
We have identified potential risks associated with the 
execution of the study (including potential sources of bias 
and issues of participant safety), and also considered and 
documented our strategy for managing these risks. These 
risks and management strategies are shown in table 1.
ConClusIons
The trends observed in New Zealand with respect to TC 
incidence may provide us with a unique opportunity to 
learn more about the currently obscure exposures that 
cause TC, by explaining why Māori have the highest rates 
of this disease in New Zealand. Using a case–control study 
design and techniques from epidemiology and genetics, 
our experienced research team aims to identify the key 
exposures in the development of TC in New Zealand, 
with a focus on those factors which might explain the 
incidence disparity between Māori and non-Māori men. 
By identifying these points of difference, we will increase 
international understanding of the key exposures which 
lead to the development of TC.3 14
Given the many exposures that have been studied, it 
is possible that the observed disparity is not likely to be 
the result of a single exposure, but rather the result of 
two or more risk factors that interact to confer increased 
TC risk to the Māori population. However, this cannot be 
answered until the completion of our study.
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